Cerity Partners
TEVA icon

Cerity Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Cerity Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.61M Buy
106,508
+21,094
+25% +$703K ﹤0.01% 1266
2026
Q1 		$2.57M Sell
85,414
-12,489
-13% -$402K ﹤0.01% 1338
2025
Q4 		$3.06M Buy
97,903
+60,507
+162% +$1.49M ﹤0.01% 1169
2025
Q3 		$755K Sell
37,396
-8,441
-18% -$148K ﹤0.01% 1742
2025
Q2 		$768K Buy
45,837
+1,291
+3% +$20.8K ﹤0.01% 1647
2025
Q1 		$685K Sell
44,546
-3,166
-7% -$56.6K ﹤0.01% 1601
2024
Q4 		$981K Buy
47,712
+6,311
+15% +$115K ﹤0.01% 1417
2024
Q3 		$746K Sell
41,401
-2,361
-5% -$41.3K ﹤0.01% 1551
2024
Q2 		$711K Buy
43,762
+1,649
+4% +$25.4K ﹤0.01% 1378
2024
Q1 		$594K Buy
42,113
+24,085
+134% +$304K ﹤0.01% 1521
2023
Q4 		$188K Buy
+18,028
New +$168K ﹤0.01% 1730
2019
Q1 		– Sell
-18,506
Closed -$285K – 573
2018
Q4 		$285K Buy
18,506
+3,931
+27% +$80.6K 0.02% 413
2018
Q3 		$314K Sell
14,575
-82
-0.6% -$1.9K 0.02% 411
2018
Q2 		$356K Buy
14,657
+2,971
+25% +$60.6K 0.03% 389
2018
Q1 		$200K Sell
11,686
-1,297
-10% -$25.3K 0.02% 503
2017
Q4 		$246K Buy
+12,983
New +$195K 0.02% 487

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cerity Partners's TEVA Position: Q2 2026 in Review

Cerity Partners increased its Teva Pharmaceuticals (TEVA) stake by 25% in Q2 2026, buying an estimated $703K and bringing the position to 106,508 shares worth $3.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1266.

Cerity Partners first reported a position in TEVA in Q4 2017 and has held it in 16 quarters since. 639 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Cerity Partners held 106,508 shares of Teva Pharmaceuticals worth $3.61M as of Q2 2026.
  • Cerity Partners bought 21,094 Teva Pharmaceuticals shares in Q2 2026, an estimated $703K.
  • Teva Pharmaceuticals made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #1266 holding.
  • Cerity Partners first reported a position in Teva Pharmaceuticals in Q4 2017 and has held it in 16 quarters since.
  • 639 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.